A

n alternative to EpiPen is about to return to the marketplace, but with a complicated pricing strategy that may appeal to some consumers, but not necessarily to insurers.

Starting next month, Kaleo will begin selling its Auvi-Q allergic-reaction device for $360 in cash to people without insurance. But the company will cover the cost entirely for those with high-deductible insurance plans or who have a household income less than $100,000 and also lack insurance.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy